An inhibitor of FAS (IC50 = 3.71 μM for the human recombinant enzyme); inhibits tritiated acetate incorporation into lipids (IC50 = 5.84 μM), increases ceramide accumulation, and induces the formation of lipid droplets in BT474 HER2+ breast cancer cells; has antiproliferative activity against non-tumorigenic MCF-10A and tumorigenic MCF-7, MDA-MB-468, BT474, and SK-BR-3 breast cancer cells; reduces tumor volume and increases survival in the murine MMTV-Neu model of HER2+ breast cancer; potentiates carboplatin response in vivo, increasing the objective response rate of stable disease from 25% for carboplatin alone to 88% for carboplatin with fasnall,